CFDE Data Portal | Search RNU2-2

	Label	Description
	RNU2-2 Gene (Entity type)	ENSG00000222328 - RNA, U2 small nuclear 2
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228430 FABP5 inhibition Huh-7 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE93156 idelalisib B cell 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE171692 FXN knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115542 digoxin 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

RNU2-2

ENSG00000222328 - RNA, U2 small nuclear 2

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE220806 progesterone fibroblast 1 v 3 human dn

A Gene Set from LINCS

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE228430 FABP5 inhibition Huh-7 2 v 0 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE93156 idelalisib B cell 1 v 0 human dn

A Gene Set from LINCS

GSE171692 FXN knockdown 1 v 0 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up

A Gene Set from LINCS

GSE115542 digoxin 2 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.